October 23, 2015 : Episode 1

Video

Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More

Related Videos
Chandler Park, MD, FACP, genitourinary medical oncologist, Norton Cancer Institute
Ann S. LaCasce, MD, MMSc
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Ashkan Emadi, MD, PhD
Peter Riedell, MD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Eunice S. Wang, MD
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Related Content
US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Naseema Gangat, MBBS, of Mayo Clinic
January 13th 2025

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Christopher Graham, MD, of University of Minnesota Medical School
January 10th 2025

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL